Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Study on Ponatinib and Imatinib for Adults with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Germany
  • Study of Ruxolitinib and Chemotherapy Drug Combination for Children with Acute Lymphoblastic Leukemia and JAK/STAT Pathway Activation

    Recruiting

    4 1 1 1
    Investigated Diseases:
    Poland
  • Study on CART 19/22 T Cells and CART45RA-NKG2D Cells for Treating Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents, and Young Adults

    Recruiting

    1 1 1
    Investigated Diseases:
    Spain
  • Infusion Study of ARI-0001 Cells for Patients with Resistant or Refractory CD19+ Acute Lymphoid Leukemia

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Spain
  • Study of Ponatinib and Chemotherapy for Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

    Recruiting

    2 1 1 1
    Italy
  • Study on the Safety and Effects of AUTO1, Cyclophosphamide, and Fludarabine Phosphate in Children with Relapsed or Refractory B-cell Leukemia and Non-Hodgkin Lymphoma

    Recruiting

    1 1 1 1
    Investigated Diseases:
    Spain
  • Study on Trametinib, Dexamethasone, Cyclophosphamide, and Cytarabine for Children with Relapsed or Refractory Blood Cancer

    Recruiting

    1 1 1 1
    Investigated Drugs:
    Austria Belgium Denmark Finland France Germany +5
  • Study on Methotrexate and Dexamethasone for Infants Under One Year with Acute Lymphoblastic Leukemia

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Austria Belgium Czechia Denmark Finland France +13
  • Study on Tioguanine and Drug Combination for Patients Aged 0-45 with Newly Diagnosed Acute Lymphoblastic Leukemia

    Recruiting

    4 1 1 1
    Belgium Denmark Estonia Finland France Germany +8
  • Study on Blinatumomab, Ponatinib, and Isatuximab for Adults Aged 18-65 with Newly Diagnosed Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma

    Recruiting

    4 1 1 1
    Belgium France